CARE Ratings reaffirms Zim Laboratories at CARE BBB, outlook Stable
Zim Laboratories (NSE: ZIMLAB) said CARE Ratings has reaffirmed its credit rating at CARE BBB with a stable outlook. The company is valued at about ₹753 crore.
What happened
Zim Laboratories (NSE: ZIMLAB) informed the stock exchanges on 8 October 2026 at 08:17 PM that CARE Ratings has reaffirmed its credit rating at CARE BBB with a stable outlook.
From the filing: "Crores) Rating Long-term bank facilities 127.48 CARE BBB;"
Company snapshot
Zim Laboratories is a micro-cap company, with a market value of about ₹753 crore.
The stock last traded at ₹140.5, against a 52-week range of ₹59.31–₹152.5 (7.8% below the high).
Before this filing the shares had moved +13.5% over the month and +26.5% over three months. Average daily turnover over the last 20 sessions was about ₹2.33 crore.
Promoters held 30.36% at the end of Q1 FY27. Foreign institutions owned 0.03% and domestic institutions 1.33%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 72 | -1.9 | -0.38 |
| Q2 FY26 | 89 | -0.4 | -0.09 |
| Q3 FY26 | 109 | 4.4 | 0.9 |
| Q4 FY26 | 105 | 3.7 | 0.76 |
| Q1 FY27 | 94 | -4 | -0.75 |
What history shows
BCEIE has no earlier credit rating filing from this company on record since May 2026.
Market-wide, 1,252 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.